Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
Kranti Bhavana 1 Article
Quality of life in patients treated for COVID-19–associated mucormycosis at a tertiary care hospital
Pragya Kumar, Rajath Rao UR, Nilanjan Roy, Deepika Agrawal, Shamshad Ahmad, Kranti Bhavana
Osong Public Health Res Perspect. 2023;14(2):119-128.   Published online April 18, 2023
DOI: https://doi.org/10.24171/j.phrp.2022.0307
  • 2,356 View
  • 64 Download
  • 1 Web of Science
  • 1 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDF
Objectives
Coronavirus disease 2019 (COVID-19)–associated mucormycosis (CAM) has emerged as a formidable infection in patients with COVID-19. The aggressive management of CAM affects quality of life (QOL); thus, this study was designed to assess the QOL in patients with CAM at a tertiary healthcare institution.
Methods
This cross-sectional study of 57 patients with CAM was conducted over 6 months using a semi-structured standard questionnaire (the abbreviated World Health Organization Quality of Life questionnaire [WHO-BREF]) and a self-rated improvement (SRI) scale ranging from 0 to 9. Cut-off values of ≤52 and <7 were considered to indicate poor QOL and poor improvement, respectively. The correlations of QOL and SRI scores were evaluated using Spearman rho values.
Results
In total, 27 patients (47.4%; 95% confidence interval [CI], 34.9%–60.1%) and 26 patients (45.6%; 95% CI, 33.4%–58.4%) had poor QOL and poor SRI scores, respectively. The overall median (interquartile range) QOL score was 52 (41–63). Headache (adjusted B, −12.3), localized facial puffiness (adjusted B , −16.4), facial discoloration (adjusted B, −23.4), loosening of teeth (adjusted B, −18.7), and facial palsy (adjusted B, −38.5) wer e significantly associated with the QOL score in patients with CAM.
Conclusion
Approximately 1 in 2 patients with CAM had poor QOL and poor improvement. Various CAM symptoms were associated with QOL in these patients. Early recognition is the key to optimal treatment, improved outcomes, and improved QOL in patients with CAM.

Citations

Citations to this article as recorded by  
  • WHO BREF Quality of Life Score as a Prognostic Indicator of Survival in Patients recovered from COVID-19 Associated Rhino-Orbito-Cerebral Mucormycosis
    K. Nidhin Das, Vidhu Sharma, Vishudh Mohan, Kapil Soni, Ankita Chugh, Bikram Choudhury, Amit Goyal
    Indian Journal of Otolaryngology and Head & Neck S.2024;[Epub]     CrossRef

PHRP : Osong Public Health and Research Perspectives